Trial reportJournal of the American College of Cardiology2016
Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
Trial report in Journal of the American College of Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00995930 (A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus.Frontiers in immunology · 2023Pooled it
- Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients.Seminars in immunopathology · 2019Pooled it
- A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.Vascular medicine (London, England) · 2019Trial
- Triglyceride-glucose-based predictive model for in-hospital mortality in older acute myocardial infarction patients with multimorbidity.Internal and emergency medicine · 2026Article
- Anti-inflammatory therapies to prevent cardiovascular events: systematic review and network meta-analysis of randomised controlled trials.Frontiers in cardiovascular medicine · 2026Review
- Imbalances in circulating monocyte and high-density lipoprotein cholesterol exacerbates the residual risk of incident myocardial infarction beyond LDL-C: a real-life, prospective cohort study.Journal of translational medicine · 2025Article
- Prognostic value of atherogenic index of plasma on the all-cause and causes-specific mortality among patients with metabolic dysfunction-associated steatotic liver disease.Diabetology & metabolic syndrome · 2025Article
- TLR2 promotes the progression of diabetes mellitus with atherosclerosis via activating NLRP3 inflammasome and MyD88/NF-κB signaling pathway.Scientific reports · 2025Article
- Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes.Cardiovascular research · 2024Review
- Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review.Cardiology and therapy · 2024Review
- Review
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review).Molecular medicine reports · 2024Review
- Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis.Nature cardiovascular research · 2024Article
- Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes.Life (Basel, Switzerland) · 2023Review
- Inflammasomes and Atherosclerosis: a Mixed Picture.Circulation research · 2023Review
- Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence.Journal of clinical medicine · 2023Review
- Inhibition of GSDMD activation by Z-LLSD-FMK or Z-YVAD-FMK reduces vascular inflammation and atherosclerotic lesion development in ApoEFrontiers in pharmacology · 2023Article
- LncRNA AC040162.3 Promotes HCV-Induced T2DM Deterioration through the miRNA-223-3p/NLRP3 Molecular Axis.Analytical cellular pathology (Amsterdam) · 2023Article
- The role of NLRP3 inflammasome in inflammation-related skeletal muscle atrophy.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundEvidence suggests that interleukin (IL)-1β is important in the pathogenesis of atherosclerosis and its complications and that inhibiting IL-1β may favorably affect vascular disease progression.
objectivesThe goal of this study was to evaluate the effects of IL-1β inhibition with canakinumab versus placebo on arterial structure and function, determined by magnetic resonance imaging.
methodsPatients (N = 189) with atherosclerotic disease and either type 2 diabetes mellitus or impaired glucose tolerance were randomized to receive placebo (n = 94) or canakinumab 150 mg monthly (n = 95) for 12 months. They underwent magnetic resonance imaging of the carotid arteries and aorta.
resultsThere were no statistically significant differences between canakinumab compared with placebo in the primary efficacy and safety endpoints. There was no statistically significant change in mean carotid wall area and no effect on aortic distensibility, measured at 3 separate anatomic sites. The change in mean carotid artery wall area was -3.37 mm
conclusionsThere were no statistically significant effects of canakinumab on measures of vascular structure or function. Canakinumab reduced markers of inflammation (high-sensitivity C-reactive protein and interleukin-6), and there were modest increases in levels of total cholesterol and triglycerides. (Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients; NCT00995930).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.